An interventional study of AI-assisted EGGIM scoring and Conventional EGGIM scoring in Gastric Intestinal Metaplasia, sponsored by Qilu Hospital of Shandong University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Qilu Hospital of Shandong University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Metaplasia with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Metaplasia · China.
Among the 23 studies in Metaplasia with a site in China, this one is the 12th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 21st registered.
45 studies on the registry are indexed under Metaplasia; 11 are open to participants now.
Browse Metaplasia studies →6 of the 23 studies in Metaplasia with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 40–75
Yongquan Shi · Sites in China
Ages 18–75
Yongquan Shi · Sites in China
Ages 18–75
Qilu Hospital of Shandong University · Sites in China
Shandong University · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 7 Metaplasia studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 100 across 26 interventional studies indexed under Metaplasia.
Median enrollment 162 across the 12 interventional studies, 540 across the 11 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 23 has an industry lead sponsor. The 4 most frequent:
Qilu Hospital of Shandong University is the lead sponsor of 311 studies on the registry; 188 are open to participants now.
Qilu Hospital of Shandong University has 3 studies filed under Metaplasia — fewer than ten, so there is no comparison to draw.
2 of the studies in Metaplasia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07915843Qilu Hospital of Shandong UniversityMulti-center Prospective Validation of Real-Time AI-EGGIM System | 2027-03-31 |
| NCT07257796Qilu Hospital of Shandong UniversityArtificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Metaplasia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective randomized controlled trial with a crossover design incorporated image-enhanced endoscopy (IEE) videos demonstrating complete standardized examinations of five standard gastric areas (antrum greater curvature, antrum lesser curvature, incisura, corpus lesser curvature, and corpus greater curvature). Endoscopists were stratified by experience level and randomly assigned to either the AI-assisted scoring first group, which performed EGGIM scoring with AI assistance in the initial phase followed by conventional scoring after a washout period, or the conventional scoring first group, which completed the assessments in reverse order. The study primarily evaluated the training efficacy of the EGGIM-AI system for improving endoscopists' EGGIM scoring performance by comparing diagnostic accuracy metrics, including the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity between groups at different study phases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Endoscopists who have performed ≥50 image-enhanced endoscopy (IEE) procedures per year and demonstrated competency in performing standardized IEE.
Exclusion Criteria:
Endoscopists who participated in data acquisition or were unblinded to patients' identifiable information and clinical data.
Endoscopists will first evaluate the videos with the assistance of the AI system via EGGIM score, and after the washout period, the videos will be evaluated again without the assistance of the AI system.
Diagnostic Test: AI-assisted EGGIM scoring
Endoscopists will first evaluate the videos without the assistance of the AI system via EGGIM score, and after the washout period, the videos will be evaluated again with the assistance of the AI system.
Diagnostic Test: Conventional EGGIM scoring
Endoscopists will evaluate the videos with the assistance of the AI system via EGGIM score.
Endoscopists will evaluate the videos without the assistance of the AI system via EGGIM score.
Efficacy of the EGGIM-AI system for improving endoscopists' EGGIM scoring performance
Diagnostic accuracy metrics, including the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity between groups at different study phases.
Time frame: Through study completion, an average of 3 months
Performance of EGGIM scoring by endoscopists with varying experience levels
Differences in AUC, sensitivity, and specificity of EGGIM scores between experienced and inexperienced endoscopists within each group at different phases.
Time frame: Through study completion, an average of 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Hospital of Shandong University →